The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches

• Published in: Cytotherapy (Oxford, England) Vol. 16; no. 7; pp. 927 - 933
• Main Authors: Jain, Natasha A., Lu, Kit, Ito, Sawa, Muranski, Pawel, Hourigan, Christopher S., Haggerty, Janice, Chokshi, Puja D., Ramos, Catalina, Cho, Elena, Cook, Lisa, Childs, Richard, Battiwalla, Minoo, Barrett, A. John
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.07.2014
• Subjects: Adolescent; Adult; Advanced Basic Science; Aged; antiviral cellular therapy; Child; CMV reactivation; Cost of Illness; Cytomegalovirus - genetics; Cytomegalovirus - pathogenicity; Cytomegalovirus Infections - economics; Cytomegalovirus Infections - pathology; Cytomegalovirus Infections - virology; economic cost; Female; Hematologic Neoplasms - mortality; Hematologic Neoplasms - pathology; Hematologic Neoplasms - therapy; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - economics; Humans; Male; Middle Aged; Other; pre-emptive therapy; Risk Factors; T-Lymphocytes - immunology; T-Lymphocytes - pathology; T-Lymphocytes - virology; Tissue Donors; Transplantation, Homologous - adverse effects; Transplantation, Homologous - economics; Virus Activation - genetics; economic cost; CMV reactivation; pre-emptive therapy; antiviral cellular therapy

Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV reactivation with vaccines and antiviral T cell...